(Q37660663)

21 August 2017

1 reference

title

Lipid abnormalities in renal disease (English)

1 reference

21 August 2017

Appel G

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 1991

1 reference

21 August 2017

1 reference

21 August 2017

volume

39

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

169-183

1 reference

The nephrotic syndrome and its complications

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipidemia in renal failure: phenotypes and pathogenetic mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipid abnormalities in uremia, dialysis, and transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

High-density lipoproteins and the risk of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Management of hyperlipidemia of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Gemfibrozil, lipids, and coronary risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Extrarenal complications of the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Cardiovascular Disease and the Nephrotic Syndrome: the other Side of the Coin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Serum lipid and lipoprotein alterations in nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipid and apolipoprotein levels in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

High-density lipoprotein cholesterol in patients with untreated and treated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Serum and urinary high density lipoproteins in glomerular disease with proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Urinary high density lipoprotein in minimal change glomerular disease and chronic glomerulopathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Secretion of lipoproteins, apolipoprotein A-I and apolipoprotein E by isolated and perfused liver of rat with experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Increased hepatitic cholesterol production due to liver hypertrophy in rat experimental nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The mechanism of hyperlipidaemia in nephrotic syndrome--role of low albumin and the LCAT reaction

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Impaired renal mevalonate metabolism in nephrotic syndrome: a stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Probucol inhibits oxidative modification of low density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Accelerated atherosclerosis in prolonged maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The role of hypertension in hemodialysis-associated atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Arterial calcification and pathology in uremic patients undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Putative atherogenic factors in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Prevalence of serum lipid abnormalities in chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Plasma High-Density Lipoprotein Concentrations in Chronic-Hemodialysis and Renal-Transplant Patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipoproteins and apolipoproteins during the progression of chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Apoprotein A and Apoprotein B in Patients with Chronic Renal Failure Undergoing Hemodialysis and in Renal Graft Recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Racial differences in plasma high-density lipoproteins in patients receiving hemodialysis. A possible mechanism for accelerated atherosclerosis in white men

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Increase in Lipoprotein Lipase during Clofibrate Treatment of Hypertriglyceridemia in Patients on Hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Dietary treatment of hyperlipidemia in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Long-term dietary treatment of hyperlipidaemia in patients treated with chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Response of plasma triglycerides to dietary change in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Chronic clofibrate therapy in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Persistent hyperlipidemia in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipid Disorders in Renal Transplant Recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipidemia After Renal Transplantation: Natural History and Pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Class II antigen expression by keratinocytes and enterocytes--an early feature of graft-versus-host-disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Hyperlipidaemia after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effect of alternate-day prednisone on plasma lipids in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Heparin-Released Plasma Lipases in Chronic Renal Failure and after Renal Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Focal and segmental glomerulosclerosis: analogies to atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Interactions of low density lipoprotein with rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Intraglomerular lipid deposition in experimental focal glomerular sclerosis in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Renal injury of diet-induced hypercholesterolemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Glomerular disease in hypercholesterolemia guinea pigs: A pathogenetic study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

The nephrotic syndrome: a complication of massive obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.22

7 January 2021

Identifiers

DOI

10.1038/KI.1991.22

1 reference

21 August 2017

1 reference